uracil has been researched along with Body Weight in 64 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "0 g/kg food) provided significant protection against elevation of blood pressure and cardiac hypertrophy in male rats treated with desoxycorticosterone trimethylacetate (DTMA) (5." | 7.65 | Effect of some substituted pyrimidines on development of desoxycorticosterone-induced hypertension in rats. ( Fregly, MJ; Rubin, ML, 1977) |
| "Peroxisome proliferator-activated receptor-γ (PPARγ) agonists like pioglitazone (PGZ) are effective antidiabetic drugs, but they induce fluid retention and body weight (BW) gain." | 3.80 | Dipeptidyl peptidase IV inhibitor lowers PPARγ agonist-induced body weight gain by affecting food intake, fat mass, and beige/brown fat but not fluid retention. ( Czogalla, J; Eguchi, A; Feldstein, AE; Fu, Y; Gerasimova, M; Kuczkowski, A; Masuda, T; Rose, MA; Scadeng, M; Vallon, V, 2014) |
| "Five non-genotoxic chemicals previously demonstrated to be bladder cancer promoters in 36-week in vivo assays for carcinogenesis were reevaluated in a 20-week experiment in order to assess the summation influence of dietary uracil, a component of RNA, on the development of (pre)neoplastic lesions." | 3.68 | Summation effects of uracil and other promoters on epithelial lesion development in the F344 rat urinary bladder initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. ( Asamoto, M; de Camargo, JL; Fukushima, S; Kato, T; Shirai, T, 1991) |
| "Uracil is known to cause reversible urolithiasis and to induce papillomatosis in the urinary bladder of F344 rats." | 3.67 | Summation effect of uracil on the two-stage and multistage models of urinary bladder carcinogenesis in F344 rats initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. ( Fukushima, S; Masui, T; Mutai, M; Shirai, T; Takahashi, S, 1988) |
| "Uracil was administered to male and female dogs for 3 months and to male dogs for 12 months at dose levels of 0, 210, 420, 840 and 1680 mg uracil per kg body weight per day by gavage." | 3.67 | Toxicity study of uracil in dogs. ( Morita, K; Richter, WR; Spicer, EJ, 1985) |
| "0 g/kg food) provided significant protection against elevation of blood pressure and cardiac hypertrophy in male rats treated with desoxycorticosterone trimethylacetate (DTMA) (5." | 3.65 | Effect of some substituted pyrimidines on development of desoxycorticosterone-induced hypertension in rats. ( Fregly, MJ; Rubin, ML, 1977) |
| "In patients with type 2 diabetes inadequately controlled by glyburide monotherapy, the addition of alogliptin resulted in clinically significant reductions in HbA1c without increased incidence of hypoglycaemia." | 2.74 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. ( Fleck, PR; Kipnes, MS; Mekki, Q; Pratley, RE; Wilson, C, 2009) |
| " Alogliptin appears to be weight neutral and is relatively well tolerated with few adverse effects." | 2.52 | Alogliptin: safety, efficacy, and clinical implications. ( Cole, SW; Marino, AB, 2015) |
| "Pioglitazone treatment also resulted in increased expression of markers of mitochondrial biogenesis in brown adipose tissue and white adipose tissue, with mild elevations observed in animals treated with alogliptin alone." | 1.40 | Administration of pioglitazone alone or with alogliptin delays diabetes onset in UCD-T2DM rats. ( Bettaieb, A; Cummings, BP; Graham, JL; Haj, FG; Havel, PJ; Stanhope, K, 2014) |
| " These results provide a strong argument for using alogliptin in combination with pioglitazone." | 1.35 | The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. ( Asakawa, T; Kataoka, O; Moritoh, Y; Odaka, H; Takeuchi, K, 2009) |
| "The purpose of this investigation was to evaluate the effectiveness of oral 5-(phenylthio)acyclouridine (PTAU) in improving the pharmacokinetics and bioavailability of oral uridine." | 1.33 | 5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens. ( Al Safarjalani, ON; El Kouni, MH; Naguib, FN; Rais, RH; Schinazi, RF; Shi, J; Zhou, XJ, 2005) |
| " It is known to be a potent protein synthesis inhibitor, but there is mounting evidence for genotoxicity and that it metabolizes to even more toxic forms." | 1.32 | Oral toxicity of the cyanobacterial toxin cylindrospermopsin in male Swiss albino mice: determination of no observed adverse effect level for deriving a drinking water guideline value. ( Falconer, IR; Humpage, AR, 2003) |
| "However, the sensitivity to the micrometastases was high." | 1.31 | Experimental postoperative adjuvant chemotherapy by UFT using primary tumor amputation model. ( Fujioka, A; Fukushima, M; Nakano, K; Okabe, H; Saito, H; Sato, K; Takechi, T; Takeda, S; Uchida, J; Unemi, N, 2000) |
| "The effects of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil (UFT) on mammary carcinogenesis and growth of tumors induced with 7,12-dimethylbenz[a]anthracene (DMBA) were investigated in rats." | 1.29 | 1-(2-Tetrahydrofuryl)-5-fluorouracil in combination with uracil suppresses mammary carcinogenesis and growth of tumors induced with 7,12-dimethylbenz[a]anthracene in rats. ( Kudo, H; Maemura, M; Mitamura, T; Nakayama, T; Sakamoto, S; Sassa, S; Suzuki, S; Yoshimura, S, 1996) |
| "Decreased body weight was observed in mice treated with 5-FU and UFT but not in those treated with S-1." | 1.29 | [Immunotoxic effects of a new antineoplastic agent S-1 in mice--comparison with S-1, UFT and 5-FU]. ( Kouchi, Y; Maeda, Y; Morinaga, H; Ohuchida, A, 1996) |
| "Uracil was administered for 15, 10 or 5 weeks followed by BBN for 23 weeks, the total observation time being 40 weeks." | 1.28 | Lack of synergism in rat urinary tract carcinogenesis between prior uracil treatment and N-butyl-N-(4-hydroxybutyl)-nitrosamine administration. ( Asamoto, M; Fukushima, S; Ogiso, T; Okumura, M; Shirai, T, 1991) |
| "Uracil was administered during weeks 9-11 at a dietary level of 3." | 1.28 | Promoting effect of the peroxisome proliferator, clofibrate, but not di(2-ethylhexyl)phthalate, on urinary bladder carcinogenesis in F344 rats initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. ( Asakawa, E; Fukushima, S; Hagiwara, A; Ogiso, T; Tamano, S, 1990) |
| "Uracil has been shown to cause a strong proliferative response in the urinary bladder epithelium of rats and mice through calculus formation and, consequently, acts as a strong promoter in bladder carcinogenesis." | 1.28 | Strong promoting activity by uracil on urinary bladder carcinogenesis and a possible inhibitory effect on thyroid tumorigenesis in rats initiated with N-methyl-N-nitrosourea. ( Cohen, SM; Garland, EM; Mann, AM; Masui, T, 1989) |
| " 5'-DFUR was less toxic to immune organs and the functions than those by other fluorinated pyrimidines." | 1.27 | [Antitumor activity and toxicity to the immune system and intestine, of the fluorinated pyrimidines FUra, 5'-DFUR, tegafur and UFT]. ( Fujimoto, K; Ishitsuka, H; Matsuura, N; Miwa, M; Ninomiya, Y; Ryu, M, 1988) |
| "A chemosensitivity test for UFT and FT-207, which are used in long-term administration clinically, was investigated for prediction of clinical response." | 1.27 | [In vivo chemosensitivity test for UFT and FT-207. I--Subrenal capsule assay]. ( Hattori, T; Hirabayashi, N; Niimi, K; Niimoto, M; Nishiyama, M; Nosoh, Y; Tohge, T; Yamaguchi, M, 1987) |
| "Nine canine subjects confirmed to have gastric cancers by punch biopsy under gastrofiberscopy were divided into 3 group given 5 mg/kg/day of UFT for 101 days, 7." | 1.27 | [UFT therapy of experimental gastric cancer in beagles induced by ENNG]. ( Ichiki, H; Izumi, T; Kurihara, M; Miyasaka, K; Orima, H; Sasaki, Y; Tasaka, K, 1987) |
| "Contrary to bladder tumors, the incidence of renal pelvic and ureteric tumors was increased by this regimen." | 1.27 | Production of urinary tract tumors by co-administration of uracil and N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide in F344 rats. ( Croft, WA; Hayashida, S; Kamiryo, Y; Wang, CY, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (34.38) | 18.7374 |
| 1990's | 20 (31.25) | 18.2507 |
| 2000's | 9 (14.06) | 29.6817 |
| 2010's | 12 (18.75) | 24.3611 |
| 2020's | 1 (1.56) | 2.80 |
| Authors | Studies |
|---|---|
| de Moraes, ACN | 1 |
| Caires, FO | 1 |
| Imperio, GE | 1 |
| Nóbrega, RH | 1 |
| Ortiga-Carvalho, TM | 1 |
| de Magalhães, VF | 1 |
| Tosaki, T | 1 |
| Kamiya, H | 1 |
| Yamamoto, Y | 1 |
| Himeno, T | 1 |
| Kato, Y | 1 |
| Kondo, M | 1 |
| Yamada, Y | 2 |
| Inagaki, A | 1 |
| Tsubonaka, K | 1 |
| Oshiro, C | 1 |
| Katayama, T | 1 |
| Hayasaki, T | 1 |
| Nakaya, Y | 1 |
| Fujiyoshi, H | 1 |
| Nakamura, J | 1 |
| Charbonnel, B | 1 |
| Schweizer, A | 1 |
| Dejager, S | 1 |
| Masuda, T | 1 |
| Fu, Y | 1 |
| Eguchi, A | 1 |
| Czogalla, J | 1 |
| Rose, MA | 1 |
| Kuczkowski, A | 1 |
| Gerasimova, M | 1 |
| Feldstein, AE | 1 |
| Scadeng, M | 1 |
| Vallon, V | 1 |
| Pratley, RE | 2 |
| Fleck, P | 1 |
| Wilson, C | 2 |
| Marino, AB | 1 |
| Cole, SW | 1 |
| Cummings, BP | 1 |
| Bettaieb, A | 1 |
| Graham, JL | 1 |
| Stanhope, K | 1 |
| Haj, FG | 1 |
| Havel, PJ | 1 |
| Nukatsuka, M | 2 |
| Nakagawa, F | 1 |
| Takechi, T | 4 |
| Naik, H | 1 |
| Czerniak, R | 1 |
| Vakilynejad, M | 1 |
| Qin, L | 1 |
| Chong, T | 1 |
| Rodriguez, R | 1 |
| Pugazhenthi, S | 1 |
| Umano, T | 1 |
| Shiraishi, K | 1 |
| Minobe, Y | 1 |
| Yamasaki, K | 1 |
| Moritoh, Y | 2 |
| Takeuchi, K | 2 |
| Asakawa, T | 2 |
| Kataoka, O | 2 |
| Odaka, H | 2 |
| Kipnes, MS | 1 |
| Fleck, PR | 1 |
| Mekki, Q | 1 |
| Kawashima, S | 1 |
| Matsuoka, TA | 1 |
| Kaneto, H | 1 |
| Tochino, Y | 1 |
| Kato, K | 1 |
| Yamamoto, K | 1 |
| Yamamoto, T | 1 |
| Matsuhisa, M | 1 |
| Shimomura, I | 1 |
| Seino, Y | 1 |
| Fujita, T | 1 |
| Hiroi, S | 1 |
| Hirayama, M | 1 |
| Kaku, K | 1 |
| Tomassini Barbarossa, I | 1 |
| Carta, G | 1 |
| Murru, E | 1 |
| Melis, M | 1 |
| Zonza, A | 1 |
| Vacca, C | 1 |
| Muroni, P | 1 |
| Di Marzo, V | 1 |
| Banni, S | 1 |
| Humpage, AR | 1 |
| Falconer, IR | 1 |
| HASHIMOTO, S | 1 |
| CHUMAN, Y | 1 |
| Choi, SW | 1 |
| Friso, S | 1 |
| Ghandour, H | 1 |
| Bagley, PJ | 1 |
| Selhub, J | 1 |
| Mason, JB | 1 |
| Al Safarjalani, ON | 1 |
| Zhou, XJ | 1 |
| Rais, RH | 1 |
| Shi, J | 1 |
| Schinazi, RF | 1 |
| Naguib, FN | 1 |
| El Kouni, MH | 1 |
| Marchal, JA | 1 |
| Núñez, MC | 1 |
| Suárez, I | 1 |
| Díaz-Gavilán, M | 1 |
| Gómez-Vidal, JA | 1 |
| Boulaiz, H | 1 |
| Rodríguez-Serrano, F | 1 |
| Gallo, MA | 1 |
| Espinosa, A | 1 |
| Aránega, A | 1 |
| Campos, JM | 1 |
| Waters, IW | 1 |
| Fregly, MJ | 2 |
| Voss, E | 1 |
| Takashi, M | 1 |
| Sakata, T | 1 |
| Nakano, Y | 1 |
| Takagi, Y | 1 |
| Hibi, H | 1 |
| Miyake, K | 1 |
| Shirai, T | 6 |
| Uwagawa, S | 1 |
| Saito, K | 1 |
| Okuno, Y | 1 |
| Kawasaki, H | 1 |
| Yoshitake, A | 1 |
| Yamada, H | 1 |
| Fukushima, S | 8 |
| Fujioka, A | 2 |
| Saito, H | 4 |
| Nakano, K | 4 |
| Uchida, J | 4 |
| Oh-ie, S | 1 |
| Nomura, N | 1 |
| Takeda, S | 4 |
| Unemi, N | 3 |
| Ishitani, K | 1 |
| Lina, BA | 1 |
| Rutten, AA | 1 |
| Woutersen, RA | 1 |
| Sakamoto, S | 2 |
| Mizuno, M | 1 |
| Kudo, H | 2 |
| Suzuki, S | 2 |
| Kasahara, N | 1 |
| Sugiura, Y | 1 |
| Mori, T | 1 |
| Nagasawa, H | 1 |
| Fujita, F | 1 |
| Fujita, M | 1 |
| Inaba, H | 1 |
| Taguchi, T | 1 |
| Uchida, K | 1 |
| Hayashi, T | 1 |
| Nishijima, Y | 2 |
| Kasaya, T | 1 |
| Akaza, H | 1 |
| Koiso, K | 2 |
| Nemoto, R | 2 |
| Harada, M | 1 |
| Sassa, S | 1 |
| Yoshimura, S | 1 |
| Nakayama, T | 1 |
| Maemura, M | 1 |
| Mitamura, T | 1 |
| Hamada, A | 1 |
| Saneyoshi, M | 1 |
| Shimizu, S | 1 |
| Kawaguchi, T | 1 |
| Nakano, M | 1 |
| Satake, H | 1 |
| Fukushima, M | 2 |
| Kouchi, Y | 1 |
| Maeda, Y | 1 |
| Morinaga, H | 1 |
| Ohuchida, A | 1 |
| Tazawa, K | 1 |
| Sakamoto, T | 1 |
| Kuroki, Y | 1 |
| Yamashita, I | 1 |
| Okamoto, M | 1 |
| Katuyama, S | 1 |
| Fujimaki, M | 1 |
| Sato, K | 1 |
| Okabe, H | 1 |
| Forsthoefel, PF | 1 |
| Williams, ML | 1 |
| Rubin, ML | 1 |
| König, J | 1 |
| Meier-Dörzenbach, ED | 1 |
| Menge, HG | 1 |
| Müller, H | 1 |
| Padberg, G | 1 |
| Petersen-Knoche, C | 1 |
| Schäfer, H | 1 |
| Kagawa, M | 1 |
| Yamamoto, A | 1 |
| Ogawa, K | 1 |
| Shibata, MA | 1 |
| Hasegawa, R | 1 |
| Sano, M | 1 |
| de Camargo, JL | 1 |
| Kato, T | 1 |
| Asamoto, M | 2 |
| Hinotsu, S | 1 |
| Okumura, M | 1 |
| Ogiso, T | 2 |
| Hagiwara, A | 1 |
| Tamano, S | 1 |
| Asakawa, E | 1 |
| Takahashi, Y | 1 |
| Ohta, T | 1 |
| Ooi, A | 1 |
| Ogino, T | 1 |
| Mai, M | 1 |
| Masui, T | 2 |
| Mann, AM | 1 |
| Garland, EM | 1 |
| Cohen, SM | 1 |
| Ninomiya, Y | 1 |
| Ryu, M | 1 |
| Matsuura, N | 1 |
| Fujimoto, K | 1 |
| Miwa, M | 1 |
| Ishitsuka, H | 1 |
| Kagawa, S | 1 |
| Takigawa, H | 1 |
| Aga, Y | 1 |
| Kurokawa, K | 1 |
| Nishiyama, M | 1 |
| Niimi, K | 1 |
| Yamaguchi, M | 1 |
| Hirabayashi, N | 1 |
| Nosoh, Y | 1 |
| Tohge, T | 1 |
| Niimoto, M | 1 |
| Hattori, T | 1 |
| Kurihara, M | 1 |
| Izumi, T | 1 |
| Ichiki, H | 1 |
| Tasaka, K | 1 |
| Orima, H | 1 |
| Miyasaka, K | 1 |
| Sasaki, Y | 1 |
| Yamada, K | 1 |
| Takao, S | 1 |
| Ishizawa, T | 1 |
| Shimazu, H | 1 |
| Hozawa, J | 1 |
| Mori, I | 1 |
| Matsubara, A | 1 |
| Tanita, J | 1 |
| Fujita, S | 1 |
| Takahashi, S | 1 |
| Mutai, M | 1 |
| Wang, CY | 1 |
| Kamiryo, Y | 1 |
| Hayashida, S | 1 |
| Croft, WA | 1 |
| Spicer, EJ | 1 |
| Richter, WR | 1 |
| Morita, K | 1 |
| Baker, DH | 1 |
| Molitoris, BA | 1 |
| Worden, AN | 1 |
| Noel, PR | 1 |
| Mawdesley-Thomas, LE | 1 |
| Palmer, AK | 1 |
| Fletcher, MA | 1 |
| Aonuma, S | 1 |
| Hama, T | 1 |
| Tamaki, N | 1 |
| Okumura, H | 1 |
| Garbuz, VM | 1 |
| Pearl, W | 1 |
| Kupfer, D | 1 |
| Oreshchenko, NI | 1 |
| Bottoms, GD | 1 |
| McCracken, MD | 1 |
| Carlton, WW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Alogliptin Plus Metformin, Alogliptin Alone, or Metformin Alone in Subjects With Type 2 Diabetes[NCT01023581] | Phase 3 | 784 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With a Sulfonylurea in Subjects With Type 2 Diabetes[NCT00286468] | Phase 3 | 500 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| A Phase 2/3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With α-glucosidase Inhibitor in Subjects With Type 2 Diabetes in Japan[NCT01263483] | Phase 2/Phase 3 | 230 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A Long-term, Open-label Extension Study to Investigate the Long-term Safety of SYR-322 When Used in Combination With α-glucosidase Inhibitor in Subjects With Type 2 Diabetes in Japan[NCT01263509] | Phase 2/Phase 3 | 179 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). (NCT01023581)
Timeframe: Baseline and Week 26.
| Intervention | percentage glycosylated hemoglobin (Least Squares Mean) |
|---|---|
| Placebo | 0.15 |
| Alogliptin 25 QD | -0.52 |
| Alogliptin 12.5 BID | -0.56 |
| Metformin 500 BID | -0.65 |
| Metformin 1000 BID | -1.11 |
| Alogliptin 12.5 BID + Metformin 500 BID | -1.22 |
| Alogliptin 12.5 BID + Metformin 1000 BID | -1.55 |
The change from Baseline in fasting plasma glucose was assessed at Weeks 1, 2, 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as fixed effects, and baseline fasting plasma glucose as a covariate. (NCT01023581)
Timeframe: Baseline and Weeks 1, 2, 4, 8, 12, 16, 20 and 26.
| Intervention | mg/dL (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 1 (n=102, 103, 94, 95, 104, 101, 109) | Week 2 (n=105, 112, 105, 102, 108, 106, 111) | Week 4 (n=105, 112, 106, 106, 110, 106, 111) | Week 8 (n=105, 112, 106, 106, 110, 106, 112) | Week 12 (n=105, 112, 106, 106, 110, 106, 112) | Week 16 (n=105, 112, 106, 106, 110, 106, 112) | Week 20 (n=105, 112, 106, 106, 110, 106, 112) | Week 26 (n=105, 112, 106, 106, 110, 106, 112) | |
| Alogliptin 12.5 BID | -11.9 | -11.6 | -16.6 | -12.1 | -14.7 | -14.7 | -12.3 | -9.7 |
| Alogliptin 12.5 BID + Metformin 1000 BID | -36.3 | -43.6 | -44.1 | -43.8 | -44.7 | -47.7 | -44.6 | -45.9 |
| Alogliptin 12.5 BID + Metformin 500 BID | -32.7 | -34.5 | -37.6 | -32.9 | -31.6 | -35.9 | -33.8 | -31.7 |
| Alogliptin 25 QD | -3.9 | -7.4 | -11.5 | -10.9 | -9.7 | -7.1 | -9.2 | -6.1 |
| Metformin 1000 BID | -23.1 | -22.2 | -29.0 | -30.7 | -30.7 | -33.5 | -35.1 | -31.9 |
| Metformin 500 BID | -12.6 | -14.5 | -16.9 | -11.8 | -14.0 | -13.3 | -10.9 | -11.5 |
| Placebo | 5.7 | 4.6 | 7.2 | 7.1 | 11.6 | 10.1 | 8.7 | 12.4 |
"The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) was assessed at Weeks 4, 8, 12, 16 and 20.~Least squares means are from an analysis of covariance (ANCOVA) model with treatment and geographic region as fixed effects, and baseline HbA1c as a covariate." (NCT01023581)
Timeframe: Baseline and Weeks 4, 8, 12, 16, and 20.
| Intervention | percentage glycosylated hemoglobin (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Week 4 (n=95, 97, 89, 94, 102, 94, 101) | Week 8 (n=102, 104, 104, 103, 108, 102, 111) | Week 12 (n=102, 104, 104, 103, 108, 102, 111) | Week 16 (n=102, 104, 104, 103, 108, 102, 111) | Week 20 (n=102, 104, 104, 103, 108, 102, 111) | |
| Alogliptin 12.5 BID | -0.42 | -0.58 | -0.62 | -0.63 | -0.59 |
| Alogliptin 12.5 BID + Metformin 1000 BID | -0.75 | -1.17 | -1.40 | -1.50 | -1.54 |
| Alogliptin 12.5 BID + Metformin 500 BID | -0.70 | -1.08 | -1.22 | -1.26 | -1.25 |
| Alogliptin 25 QD | -0.34 | -0.51 | -0.53 | -0.58 | -0.57 |
| Metformin 1000 BID | -0.58 | -0.86 | -1.02 | -1.09 | -1.14 |
| Metformin 500 BID | -0.37 | -0.59 | -0.68 | -0.72 | -0.68 |
| Placebo | 0.09 | 0.08 | 0.12 | 0.13 | 0.12 |
The change between Body Weight measured at week 12 and Body Weight measured at baseline. (NCT00286468)
Timeframe: Baseline and Week 12.
| Intervention | kg (Least Squares Mean) |
|---|---|
| Placebo | -0.12 |
| Alogliptin 12.5 mg QD | 0.58 |
| Alogliptin 25 mg QD | 0.40 |
The change between Body Weight measured at week 20 and Body Weight measured at baseline. (NCT00286468)
Timeframe: Baseline and Week 20.
| Intervention | kg (Least Squares Mean) |
|---|---|
| Placebo | -0.30 |
| Alogliptin 12.5 mg QD | 0.79 |
| Alogliptin 25 mg QD | 0.61 |
The change between Body Weight measured at week 26 or final visit and Body Weight measured at baseline. (NCT00286468)
Timeframe: Baseline and Week 26.
| Intervention | kg (Least Squares Mean) |
|---|---|
| Placebo | -0.20 |
| Alogliptin 12.5 mg QD | 0.60 |
| Alogliptin 25 mg QD | 0.68 |
The change between Body Weight measured at week 8 and Body Weight measured at baseline. (NCT00286468)
Timeframe: Baseline and Week 8.
| Intervention | kg (Least Squares Mean) |
|---|---|
| Placebo | -0.27 |
| Alogliptin 12.5 mg QD | 0.47 |
| Alogliptin 25 mg QD | 0.33 |
The change between the value of C-peptide collected at week 12 and C-peptide collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 12.
| Intervention | ng/mL (Least Squares Mean) |
|---|---|
| Placebo | -0.020 |
| Alogliptin 12.5 mg QD | 0.162 |
| Alogliptin 25 mg QD | 0.206 |
The change between the value of C-peptide collected at week 16 and C-peptide collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 16.
| Intervention | ng/mL (Least Squares Mean) |
|---|---|
| Placebo | -0.007 |
| Alogliptin 12.5 mg QD | 0.222 |
| Alogliptin 25 mg QD | 0.153 |
The change between the value of C-peptide collected at week 20 and C-peptide collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 20.
| Intervention | ng/mL (Least Squares Mean) |
|---|---|
| Placebo | -0.016 |
| Alogliptin 12.5 mg QD | -0.001 |
| Alogliptin 25 mg QD | 0.122 |
The change between the value of C-peptide collected at week 26 or final visit and C-peptide collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 26.
| Intervention | ng/mL (Least Squares Mean) |
|---|---|
| Placebo | -0.215 |
| Alogliptin 12.5 mg QD | -0.140 |
| Alogliptin 25 mg QD | -0.153 |
The change between the value of C-peptide collected at week 4 and C-peptide collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 4.
| Intervention | ng/mL (Least Squares Mean) |
|---|---|
| Placebo | -0.041 |
| Alogliptin 12.5 mg QD | 0.122 |
| Alogliptin 25 mg QD | 0.136 |
The change between the value of C-peptide collected at week 8 and C-peptide collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 8.
| Intervention | ng/mL (Least Squares Mean) |
|---|---|
| Placebo | -0.176 |
| Alogliptin 12.5 mg QD | 0.092 |
| Alogliptin 25 mg QD | 0.173 |
The change between the value of fasting plasma glucose collected at final visit or week 1 and fasting plasma glucose collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 1.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | 0.3 |
| Alogliptin 12.5 mg QD | -11.8 |
| Alogliptin 25 mg QD | -19.0 |
The change between the value of fasting plasma glucose collected at week 12 and fasting plasma glucose collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 12.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -3.4 |
| Alogliptin 12.5 mg QD | -13.5 |
| Alogliptin 25 mg QD | -15.0 |
The change between the value of fasting plasma glucose collected at week 16 and fasting plasma glucose collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 16.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -7.1 |
| Alogliptin 12.5 mg QD | -9.0 |
| Alogliptin 25 mg QD | -13.0 |
The change between the value of fasting plasma glucose collected at week 2 and fasting plasma glucose collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 2.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -1.8 |
| Alogliptin 12.5 mg QD | -16.7 |
| Alogliptin 25 mg QD | -21.8 |
The change between the value of fasting plasma glucose collected at week 20 and fasting plasma glucose collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 20.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -0.4 |
| Alogliptin 12.5 mg QD | -9.3 |
| Alogliptin 25 mg QD | -13.6 |
The change between the value of fasting plasma glucose collected at week 26 or final visit and fasting plasma glucose collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 26.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | 2.2 |
| Alogliptin 12.5 mg QD | -4.7 |
| Alogliptin 25 mg QD | -8.4 |
The change between the value of fasting plasma glucose collected at week 4 and fasting plasma glucose collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 4.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -3.7 |
| Alogliptin 12.5 mg QD | -14.6 |
| Alogliptin 25 mg QD | -21.1 |
The change between the value of fasting plasma glucose collected at week 8 and fasting plasma glucose collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 8.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -3.2 |
| Alogliptin 12.5 mg QD | -19.9 |
| Alogliptin 25 mg QD | -18.6 |
The change between the value of fasting proinsulin collected at week 12 and fasting proinsulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 12.
| Intervention | pmol/L (Least Squares Mean) |
|---|---|
| Placebo | -0.5 |
| Alogliptin 12.5 mg QD | -0.7 |
| Alogliptin 25 mg QD | -0.7 |
The change between the value of fasting proinsulin collected at week 16 and fasting proinsulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 16.
| Intervention | pmol/L (Least Squares Mean) |
|---|---|
| Placebo | -1.8 |
| Alogliptin 12.5 mg QD | -1.5 |
| Alogliptin 25 mg QD | -1.1 |
The change between the value of fasting proinsulin collected at week 20 and fasting proinsulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 20.
| Intervention | pmol/L (Least Squares Mean) |
|---|---|
| Placebo | -2.5 |
| Alogliptin 12.5 mg QD | -2.1 |
| Alogliptin 25 mg QD | 0.0 |
The change between the value of fasting proinsulin collected at week 26 or final visit and fasting proinsulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 26.
| Intervention | pmol/L (Least Squares Mean) |
|---|---|
| Placebo | -2.0 |
| Alogliptin 12.5 mg QD | -3.9 |
| Alogliptin 25 mg QD | -2.1 |
The change between the value of fasting proinsulin collected at week 4 and fasting proinsulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 4.
| Intervention | pmol/L (Least Squares Mean) |
|---|---|
| Placebo | -3.0 |
| Alogliptin 12.5 mg QD | -2.6 |
| Alogliptin 25 mg QD | 0.7 |
The change between the value of fasting proinsulin collected at week 8 and fasting proinsulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 8.
| Intervention | pmol/L (Least Squares Mean) |
|---|---|
| Placebo | -4.2 |
| Alogliptin 12.5 mg QD | -4.5 |
| Alogliptin 25 mg QD | -0.9 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 26 or final visit and glycosylated hemoglobin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 26.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | 0.01 |
| Alogliptin 12.5 mg QD | -0.38 |
| Alogliptin 25 mg QD | -0.52 |
The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 and Glycosylated Hemoglobin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 12.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -0.17 |
| Alogliptin 12.5 mg QD | -0.58 |
| Alogliptin 25 mg QD | -0.69 |
The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 16 and Glycosylated Hemoglobin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 16.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -0.16 |
| Alogliptin 12.5 mg QD | -0.53 |
| Alogliptin 25 mg QD | -0.66 |
The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 20 and Glycosylated Hemoglobin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 20.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -0.08 |
| Alogliptin 12.5 mg QD | -0.43 |
| Alogliptin 25 mg QD | -0.60 |
The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 4 and Glycosylated Hemoglobin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 4.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -0.18 |
| Alogliptin 12.5 mg QD | -0.40 |
| Alogliptin 25 mg QD | -0.46 |
The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and Glycosylated Hemoglobin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 8.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -0.18 |
| Alogliptin 12.5 mg QD | -0.57 |
| Alogliptin 25 mg QD | -0.65 |
The change between the value of insulin collected at week 12 and insulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 12.
| Intervention | mcIU/mL (Least Squares Mean) |
|---|---|
| Placebo | -0.02 |
| Alogliptin 12.5 mg QD | 1.33 |
| Alogliptin 25 mg QD | 1.00 |
The change between the value of insulin collected at week 16 and insulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 16.
| Intervention | mcIU/mL (Least Squares Mean) |
|---|---|
| Placebo | -1.21 |
| Alogliptin 12.5 mg QD | 1.74 |
| Alogliptin 25 mg QD | 0.51 |
The change between the value of insulin collected at week 20 and insulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 20.
| Intervention | mcIU/mL (Least Squares Mean) |
|---|---|
| Placebo | -0.07 |
| Alogliptin 12.5 mg QD | 1.18 |
| Alogliptin 25 mg QD | 0.93 |
The change between the value of insulin collected at week 26 and insulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 26.
| Intervention | mcIU/mL (Least Squares Mean) |
|---|---|
| Placebo | -1.89 |
| Alogliptin 12.5 mg QD | -0.85 |
| Alogliptin 25 mg QD | 0.14 |
The change between the value of insulin collected at week 4 and insulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 4.
| Intervention | mcIU/mL (Least Squares Mean) |
|---|---|
| Placebo | -0.62 |
| Alogliptin 12.5 mg QD | 0.64 |
| Alogliptin 25 mg QD | 0.89 |
The change between the value of insulin collected at week 8 and insulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 8.
| Intervention | mcIU/mL (Least Squares Mean) |
|---|---|
| Placebo | -0.81 |
| Alogliptin 12.5 mg QD | -0.62 |
| Alogliptin 25 mg QD | 0.38 |
The change between the ratio value of proinsulin and insulin collected at week 12 and the ratio value of proinsulin and insulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 12.
| Intervention | ratio (Least Squares Mean) |
|---|---|
| Placebo | -0.002 |
| Alogliptin 12.5 mg QD | -0.030 |
| Alogliptin 25 mg QD | -0.040 |
The change between the ratio value of proinsulin and insulin collected at week 16 and the ratio value of proinsulin and insulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 16.
| Intervention | ratio (Least Squares Mean) |
|---|---|
| Placebo | 0.003 |
| Alogliptin 12.5 mg QD | -0.037 |
| Alogliptin 25 mg QD | -0.041 |
The change between the ratio value of proinsulin and insulin collected at week 20 and the ratio value of proinsulin and insulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 20.
| Intervention | ratio (Least Squares Mean) |
|---|---|
| Placebo | -0.005 |
| Alogliptin 12.5 mg QD | -0.035 |
| Alogliptin 25 mg QD | -0.036 |
The change between the ratio value of proinsulin and insulin collected at week 26 or final visit and the ratio value of proinsulin and insulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 26.
| Intervention | ratio (Least Squares Mean) |
|---|---|
| Placebo | -0.008 |
| Alogliptin 12.5 mg QD | -0.034 |
| Alogliptin 25 mg QD | -0.034 |
The change between the ratio value of proinsulin and insulin collected at week 4 and the ratio value of proinsulin and insulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 4.
| Intervention | ratio (Least Squares Mean) |
|---|---|
| Placebo | -0.008 |
| Alogliptin 12.5 mg QD | -0.064 |
| Alogliptin 25 mg QD | -0.043 |
The change between the ratio value of proinsulin and insulin collected at week 8 and the ratio value of proinsulin and insulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 8.
| Intervention | ratio (Least Squares Mean) |
|---|---|
| Placebo | -0.009 |
| Alogliptin 12.5 mg QD | -0.052 |
| Alogliptin 25 mg QD | -0.045 |
The number of participants requiring rescue for failing to achieve pre-specified glycemic targets during the 26 week study. (NCT00286468)
Timeframe: 26 Weeks.
| Intervention | participants (Number) |
|---|---|
| Placebo | 28 |
| Alogliptin 12.5 mg QD | 30 |
| Alogliptin 25 mg QD | 31 |
The number of participants with a value for the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) less than or equal to 6.5% during the 26 week study. (NCT00286468)
Timeframe: Baseline and Week 26.
| Intervention | participants (Number) |
|---|---|
| Placebo | 7 |
| Alogliptin 12.5 mg QD | 19 |
| Alogliptin 25 mg QD | 28 |
The number of participants with a value for the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) less than or equal to 7.0% during the 26 week study. (NCT00286468)
Timeframe: Baseline and Week 26.
| Intervention | participants (Number) |
|---|---|
| Placebo | 18 |
| Alogliptin 12.5 mg QD | 60 |
| Alogliptin 25 mg QD | 69 |
The number of participants with a value for the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) less than or equal to 7.5% during the 26 week study. (NCT00286468)
Timeframe: Baseline and Week 26.
| Intervention | participants (Number) |
|---|---|
| Placebo | 33 |
| Alogliptin 12.5 mg QD | 94 |
| Alogliptin 25 mg QD | 112 |
The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 0.5% during the 26 week study. (NCT00286468)
Timeframe: Baseline and Week 26.
| Intervention | participants (Number) |
|---|---|
| Placebo | 26 |
| Alogliptin 12.5 mg QD | 96 |
| Alogliptin 25 mg QD | 100 |
The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 1.0% during the 26 week study. (NCT00286468)
Timeframe: Baseline and Week 26.
| Intervention | participants (Number) |
|---|---|
| Placebo | 13 |
| Alogliptin 12.5 mg QD | 38 |
| Alogliptin 25 mg QD | 59 |
The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 1.5% during the 26 week study. (NCT00286468)
Timeframe: Baseline and Week 26.
| Intervention | participants (Number) |
|---|---|
| Placebo | 7 |
| Alogliptin 12.5 mg QD | 13 |
| Alogliptin 25 mg QD | 24 |
The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 2.0% during the 26 week study. (NCT00286468)
Timeframe: Baseline and Week 26.
| Intervention | participants (Number) |
|---|---|
| Placebo | 4 |
| Alogliptin 12.5 mg QD | 5 |
| Alogliptin 25 mg QD | 12 |
The number of participants with a fasting plasma glucose value greater than or equal to 200 mg per dL during the 26 week study. (NCT00286468)
Timeframe: 26 Weeks.
| Intervention | participants (Number) |
|---|---|
| Placebo | 53 |
| Alogliptin 12.5 mg QD | 94 |
| Alogliptin 25 mg QD | 79 |
The change between the value of blood glucose collected at week 12 or final visit and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal. (NCT01263483)
Timeframe: Baseline and Week 12.
| Intervention | mg/dL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | 72.4 |
| Alogliptin 12.5 mg QD | 40.9 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 38.7 |
The change between the value of blood glucose collected at week 12 or final visit and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal. (NCT01263483)
Timeframe: Baseline and Week 12.
| Intervention | mg·hr/dL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | -4.3 |
| Alogliptin 12.5 mg QD | -74.7 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -76.8 |
The change between the value of C-peptide collected at week 12 or final visit and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal. (NCT01263483)
Timeframe: Baseline and Week 12.
| Intervention | ng·hr/mL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | 0.14 |
| Alogliptin 12.5 mg QD | 0.69 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.57 |
The change between the value of fasting C-peptide collected at week 12 or final visit and fasting C-peptide collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 12.
| Intervention | ng/mL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | 0.02 |
| Alogliptin 12.5 mg QD | 0.06 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.10 |
The change between the value of fasting C-peptide collected at week 2 and fasting C-peptide collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 2.
| Intervention | ng/mL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | 0.03 |
| Alogliptin 12.5 mg QD | -0.07 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.01 |
The change between the value of fasting C-peptide collected at week 4 and fasting C-peptide collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 4.
| Intervention | ng/mL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | 0.05 |
| Alogliptin 12.5 mg QD | 0.06 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.01 |
The change between the value of fasting C-peptide collected at week 8 and fasting C-peptide collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 8.
| Intervention | ng/mL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | 0.07 |
| Alogliptin 12.5 mg QD | 0.03 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.01 |
The change between the value of fasting plasma glucose collected at week 12 or final visit and fasting plasma glucose collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 12.
| Intervention | mg/dL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | -5.6 |
| Alogliptin 12.5 mg QD | -19.1 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -18.5 |
The change between the value of fasting plasma glucose collected at week 2 and fasting plasma glucose collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 2
| Intervention | mg/dL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | -3.5 |
| Alogliptin 12.5 mg QD | -15.5 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -18.8 |
The change between the value of fasting plasma glucose collected at week 4 and fasting plasma glucose collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 4.
| Intervention | mg/dL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | -0.6 |
| Alogliptin 12.5 mg QD | -16.2 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -22.6 |
The change between the value of fasting plasma glucose collected at week 8 and fasting plasma glucose collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 8.
| Intervention | mg/dL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | -2.5 |
| Alogliptin 12.5 mg QD | -20.8 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -21.9 |
The change between the value of glucagons collected at week 12 or final visit and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal. (NCT01263483)
Timeframe: Baseline and Week 12
| Intervention | pg·hr/mL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | -0.4 |
| Alogliptin 12.5 mg QD | -19.2 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -20.5 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 or final visit and glycosylated hemoglobin collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 12.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Voglibose 0.2 mg TID | 0.04 |
| Alogliptin 12.5 mg QD | -0.96 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.91 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 2 and glycosylated hemoglobin collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 2.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Voglibose 0.2 mg TID | -0.01 |
| Alogliptin 12.5 mg QD | -0.19 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.21 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 4 and glycosylated hemoglobin collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 4.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Voglibose 0.2 mg TID | -0.02 |
| Alogliptin 12.5 mg QD | -0.44 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.43 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 8.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Voglibose 0.2 mg TID | -0.01 |
| Alogliptin 12.5 mg QD | -0.74 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.75 |
The change between the value of insulin collected at week 12 or final visit and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal. (NCT01263483)
Timeframe: Baseline and Week 12
| Intervention | μU·hr/mL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | -2.47 |
| Alogliptin 12.5 mg QD | 4.62 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 1.50 |
The change between the value of blood glucose collected at week 52 or final visit and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 39.6 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 39.4 |
The change between the value of blood glucose collected at week 12 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 12.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 41.2 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 37.6 |
The change between the value of blood glucose collected at week 24 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 38.0 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 37.1 |
The change between the value of blood glucose collected at week 52 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 52.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 39.0 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 40.8 |
The change between the value of blood glucose collected at week 52 or final visit and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).
| Intervention | mg•hr/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -77.5 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -82.2 |
The change between the value of blood glucose collected at week 12 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 12.
| Intervention | mg•hr/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -73.2 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -76.8 |
The change between the value of blood glucose collected at week 24 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 24.
| Intervention | mg•hr/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -69.0 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -70.4 |
The change between the value of blood glucose collected at week 52 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 52.
| Intervention | mg•hr/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -83.5 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -83.4 |
The change between the value of C-peptide collected at week 52 or final visit and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).
| Intervention | ng•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 1.05 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.80 |
The change between the value of C-peptide collected at week 12 and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 12.
| Intervention | ng•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.71 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.71 |
The change between the value of C-peptide collected at week 24 and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 24.
| Intervention | ng•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 1.38 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 1.12 |
The change between the value of C-peptide collected at week 52 and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 52.
| Intervention | ng•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.96 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 2.18 |
The change between the value of fasting C-peptide collected at week 52 or final visit and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.31 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.29 |
The change between the value of fasting C-peptide collected at week 12 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 12.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.10 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.13 |
The change between the value of fasting C-peptide collected at week 16 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 16.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.24 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.21 |
The change between the value of fasting C-peptide collected at week 20 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 20.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.24 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.15 |
The change between the value of fasting C-peptide collected at week 24 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 24.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.19 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.14 |
The change between the value of fasting C-peptide collected at week 28 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 28.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.18 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.25 |
The change between the value of fasting C-peptide collected at week 32 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 32.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.47 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.31 |
The change between the value of fasting C-peptide collected at week 36 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 36.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.33 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.38 |
The change between the value of fasting C-peptide collected at week 40 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 40.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.30 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.37 |
The change between the value of fasting C-peptide collected at week 44 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 44.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.08 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.25 |
The change between the value of fasting C-peptide collected at week 48 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 48.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.45 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.38 |
The change between the value of fasting C-peptide collected at week 52 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 52.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.80 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.40 |
The change between the value of fasting C-peptide collected at week 8 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 8.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.05 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.11 |
The change between the value of fasting plasma glucose collected at week 52 or final visit and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -17.5 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -23.3 |
The change between the value of fasting plasma glucose collected at week 12 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 12.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -17.1 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -18.8 |
The change between the value of fasting plasma glucose collected at week 16 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 16.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -16.0 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -15.3 |
The change between the value of fasting plasma glucose collected at week 20 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 20.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -15.6 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -15.0 |
The change between the value of fasting plasma glucose collected at week 24 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -13.8 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -15.6 |
The change between the value of fasting plasma glucose collected at week 28 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 28.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -14.5 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -21.9 |
The change between the value of fasting plasma glucose collected at week 32 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 32.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -17.7 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -20.1 |
The change between the value of fasting plasma glucose collected at week 36 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 36.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -17.3 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -22.6 |
The change between the value of fasting plasma glucose collected at week 40 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 40.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -19.7 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -22.8 |
The change between the value of fasting plasma glucose collected at week 44 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 44.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -21.5 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -24.4 |
The change between the value of fasting plasma glucose collected at week 48 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 48.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -20.5 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -23.1 |
The change between the value of fasting plasma glucose collected at week 52 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 52.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -20.7 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -24.0 |
The change between the value of fasting plasma glucose collected at week 8 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 8.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -18.2 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -20.4 |
The change between the value of glucagons collected at week 52 or final visit and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).
| Intervention | pg•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -11.7 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -20.9 |
The change between the value of glucagons collected at week 12 and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 12.
| Intervention | pg•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -14.3 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -20.0 |
The change between the value of glucagons collected at week 24 and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 24.
| Intervention | pg•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -4.6 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -6.8 |
The change between the value of glucagons collected at week 52 and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 52.
| Intervention | pg•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -12.0 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -22.2 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 52 or final visit and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.81 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.89 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 12.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.89 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.96 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 16 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 16.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.91 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.96 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 20 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 20.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.90 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.89 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 24.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.83 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.88 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 28 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 28.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.81 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.89 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 32 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 32.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.80 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.85 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 36 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 36.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.82 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.90 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 40 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 40.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.78 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.92 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 44 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 44.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.88 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.94 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 48 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 48.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.92 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.94 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 52 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 52.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.95 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.95 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 8.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.69 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.79 |
The change between the value of insulin collected at week 52 or final visit and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).
| Intervention | μU•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.61 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.01 |
The change between the value of insulin collected at week 12 and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 12.
| Intervention | μU•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 3.05 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 2.95 |
The change between the value of insulin collected at week 24 and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 24.
| Intervention | μU•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 4.42 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 2.26 |
The change between the value of insulin collected at week 52 and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 52.
| Intervention | μU•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -1.28 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.18 |
A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug and within 30 days after receiving the last dose of study drug. A TEAE may also be a pre-treatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug, which increases in intensity after the start of dosing. Adverse events data with onset occurring more than 30 days after last dose of study drug (AE start date - last dose date >30) will be listed, but not included in the summary tables below. (NCT01263509)
Timeframe: 52 Weeks.
| Intervention | participants (Number) | ||
|---|---|---|---|
| Serious Adverse Event | Serious Adverse Event Related to Study Drug | Other Adverse Events (Incidence ≥3%) | |
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 6 | 0 | 85 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 7 | 1 | 73 |
2 reviews available for uracil and Body Weight
| Article | Year |
|---|---|
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-P | 2013 |
Alogliptin: safety, efficacy, and clinical implications.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Ther | 2015 |
3 trials available for uracil and Body Weight
| Article | Year |
|---|---|
Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combinatio | 2014 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; D | 2009 |
Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibito | 2011 |
Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibito | 2011 |
Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibito | 2011 |
Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibito | 2011 |
59 other studies available for uracil and Body Weight
| Article | Year |
|---|---|
Cylindrospermopsin Disrupts Estrous Cycle and Increases Spermatogenesis in Mice.
Topics: Alkaloids; Animals; Bacterial Toxins; Body Weight; Cyanobacteria Toxins; Endocrine Disruptors; Estra | 2022 |
Efficacy and Patient Satisfaction of the Weekly DPP-4 Inhibitors Trelagliptin and Omarigliptin in 80 Japanese Patients with Type 2 Diabetes.
Topics: Adult; Aged; Aged, 80 and over; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhi | 2017 |
Dipeptidyl peptidase IV inhibitor lowers PPARγ agonist-induced body weight gain by affecting food intake, fat mass, and beige/brown fat but not fluid retention.
Topics: Adipocytes, Brown; Adipose Tissue, Brown; Animals; Body Weight; Dipeptidyl-Peptidase IV Inhibitors; | 2014 |
Administration of pioglitazone alone or with alogliptin delays diabetes onset in UCD-T2DM rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Eating; Huma | 2014 |
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2015 |
Application of pharmacometric approaches to evaluate effect of weight and renal function on pharmacokinetics of alogliptin.
Topics: Adolescent; Adult; Aged; Biological Availability; Body Weight; Clinical Trials, Phase I as Topic; Cl | 2016 |
Glucagon-Like Peptide-1-Mediated Modulation of Inflammatory Pathways in the Diabetic Brain: Relevance to Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Blood Glucose; Body Weight; Brain; Cytokines; Diabetes Mellitus, Experim | 2016 |
Uterotrophic assay, Hershberger assay, and subacute oral toxicity study of 3-amino-1,2,4-triazole based on the Organization for Economic Co-operation and Development draft protocols.
Topics: Administration, Oral; Animals; Antithyroid Agents; Biological Assay; Body Weight; Dose-Response Rela | 2009 |
The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice.
Topics: Animals; Blood Glucose; Body Weight; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Eating; | 2009 |
Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.
Topics: Adiponectin; Animals; Blood Glucose; Body Weight; Cell Degranulation; Diabetes Mellitus, Type 2; Dip | 2009 |
Effect of alogliptin, pioglitazone and glargine on pancreatic β-cells in diabetic db/db mice.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Blood Glucose; Body Weight; Deoxyguanosine; Dipeptidyl-Peptida | 2011 |
Taste sensitivity to 6-n-propylthiouracil is associated with endocannabinoid plasma levels in normal-weight individuals.
Topics: Adult; Body Mass Index; Body Weight; Cognition; Endocannabinoids; Energy Intake; Feeding Behavior; F | 2013 |
Oral toxicity of the cyanobacterial toxin cylindrospermopsin in male Swiss albino mice: determination of no observed adverse effect level for deriving a drinking water guideline value.
Topics: Administration, Oral; Alkaloids; Animals; Bacterial Toxins; Body Weight; Cyanobacteria; Cyanobacteri | 2003 |
INFLUENCES OF URACIL UPON RIBOFLAVIN METABOLISM.
Topics: Blood Glucose; Body Weight; DNA; Feces; Glycolates; Intestines; Kidney; Liver; Metabolism; Mice; Rab | 1963 |
Vitamin B-12 deficiency induces anomalies of base substitution and methylation in the DNA of rat colonic epithelium.
Topics: Animals; Body Weight; Colon; Colorectal Neoplasms; DNA; DNA Methylation; Epithelium; Folic Acid; Gas | 2004 |
5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Biological Availability; Body Weight | 2005 |
A synthetic uracil derivative with antitumor activity through decreasing cyclin D1 and Cdk1, and increasing p21 and p27 in MCF-7 cells.
Topics: Animals; Antineoplastic Agents; Biomarkers; Body Weight; CDC2 Protein Kinase; Cell Line, Tumor; Cell | 2007 |
Effect of some substituted pyrimidines on development of renal hypertension in the rat.
Topics: Animals; Blood Pressure; Body Weight; Chlorides; Diet; Hematocrit; Hypertension, Renal; Male; Potass | 1967 |
Initiation-stage enhancement by uracil of N-ethyl-N-hydroxyethylnitrosamine-induction of kidney carcinogenesis in rats.
Topics: Adenocarcinoma; Animals; Body Weight; Carcinogens; Diethylnitrosamine; Drug Synergism; Female; Kidne | 1994 |
Lack of induction of epithelial cell proliferation by sodium saccharin and sodium L-ascorbate in the urinary bladder of NCI-black-Reiter (NBR) male rats.
Topics: Animals; Ascorbic Acid; Body Weight; Carcinogens; Cell Division; DNA; Epithelial Cells; Epithelium; | 1994 |
[Antitumor and anticachectic activity of UFT in BALB/c mice bearing colon 26 adenocarcinoma].
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cachexia; Colo | 1994 |
Effect of coffee drinking on cell proliferation in rat urinary bladder epithelium.
Topics: Animals; Body Weight; Cell Division; Cell Transformation, Neoplastic; Coffee; Drinking; Electrolytes | 1993 |
Suppression of mammary tumors by oral administration of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil in SHN virgin mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Female; Fluorouracil; Mammary | 1993 |
[Antitumor activity of BOF-A2, a new 5-fluorouracil derivative, against human cancers xenografted in nude mice by intermittent administration].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 1993 |
[Subrenal capsule assay of nude mice for testing the effectiveness of UFT for rat prostatic carcinoma (R3327)].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cisplatin; Male; Mice; Mice, I | 1993 |
[Experimental study on the combined treatment of UFT with etoposide against mouse Lewis lung carcinoma].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; DNA, Neoplasm; Etoposide; Lung | 1993 |
1-(2-Tetrahydrofuryl)-5-fluorouracil in combination with uracil suppresses mammary carcinogenesis and growth of tumors induced with 7,12-dimethylbenz[a]anthracene in rats.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined | 1996 |
Acyclothymidine alleviates intestinal toxicity of 5'-deoxy-5-fluorouridine without loss of antitumor activity in mice.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Body Weight; Carcinoma, Lewis Lung; Drug Syner | 1996 |
[Antimetastatic effects of UFT on murine liver metastasis model using L5178YHM lymphoma].
Topics: Animals; Body Weight; Drug Combinations; Floxuridine; Leukemia L5178; Liver Neoplasms; Male; Mice; T | 1996 |
[Immunotoxic effects of a new antineoplastic agent S-1 in mice--comparison with S-1, UFT and 5-FU].
Topics: Animals; Antibody Formation; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1996 |
Inhibitory effects of fluorinated pyrimidines, 5'-DFUR, UFT and T-506, in a model of hepatic metastasis of mouse colon 26 adenocarcinoma-assessment of inhibitory activity and adverse reactions at the maximum tolerated dose.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Body Weight; Colonic Neoplasms; Dose-Response Relati | 1997 |
Experimental postoperative adjuvant chemotherapy by UFT using primary tumor amputation model.
Topics: Amputation, Surgical; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinom | 2000 |
The effects of 5-fluorouracil and 5-fluorodeoxyuridine used alone and in combination with normal nucleic acid precursors on development of mice in lines selected for low and high expression of Strong's luxoid gene.
Topics: Abnormalities, Drug-Induced; Animals; Body Weight; Cell Survival; Drug Synergism; Female; Fetal Deat | 1975 |
Effect of some substituted pyrimidines on development of desoxycorticosterone-induced hypertension in rats.
Topics: Animals; Body Weight; Cardiomegaly; Desoxycorticosterone; Hematocrit; Hemoglobins; Hypertension; Mal | 1977 |
[Toxicologic study on the antihypertensive agent urapidil].
Topics: Administration, Oral; Animals; Antihypertensive Agents; Body Weight; Dogs; Drug Tolerance; Female; I | 1977 |
Uracil-induced urolithiasis in the urinary bladder of rats is irritation-dependent.
Topics: Animals; Body Weight; Hydrogen-Ion Concentration; Inflammation; Male; Organ Size; Osmolar Concentrat | 1992 |
Timing effects of uracil-induced urolithiasis on amplification of second-stage promotion in rat bladder carcinogenesis.
Topics: Animals; Bicarbonates; Body Weight; Butylhydroxybutylnitrosamine; Carcinogens; Drug Administration S | 1991 |
Summation effects of uracil and other promoters on epithelial lesion development in the F344 rat urinary bladder initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine.
Topics: Animals; Ascorbic Acid; Body Weight; Butylated Hydroxyanisole; Butylated Hydroxytoluene; Butylhydrox | 1991 |
[Effect of UFT with high dose leucovorin for transplantable bladder tumor (MBT-2) in mice].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Drug Synergism; Leucovorin; Mi | 1991 |
Lack of synergism in rat urinary tract carcinogenesis between prior uracil treatment and N-butyl-N-(4-hydroxybutyl)-nitrosamine administration.
Topics: Animals; Body Weight; Butylhydroxybutylnitrosamine; Cocarcinogenesis; Kidney Neoplasms; Kidney Pelvi | 1991 |
Promoting effect of the peroxisome proliferator, clofibrate, but not di(2-ethylhexyl)phthalate, on urinary bladder carcinogenesis in F344 rats initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine.
Topics: Animals; Body Weight; Butylhydroxybutylnitrosamine; Carcinogens; Clofibrate; Diethylhexyl Phthalate; | 1990 |
The effect of UFTM therapy on primary and metastatic colon cancer from the same human xenotransplanted into nude mice.
Topics: Adenocarcinoma, Mucinous; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Colo | 1990 |
Strong promoting activity by uracil on urinary bladder carcinogenesis and a possible inhibitory effect on thyroid tumorigenesis in rats initiated with N-methyl-N-nitrosourea.
Topics: Adenocarcinoma; Animals; Body Weight; Carcinogens; Carcinoma, Transitional Cell; Male; Methylnitroso | 1989 |
[Antitumor activity and toxicity to the immune system and intestine, of the fluorinated pyrimidines FUra, 5'-DFUR, tegafur and UFT].
Topics: Animals; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bone Marro | 1988 |
[Experimental study of UFT in prostatic carcinoma (DU-145) in nude mice].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cell Line; Cells, Cultured; Hu | 1986 |
[In vivo chemosensitivity test for UFT and FT-207. I--Subrenal capsule assay].
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Colonic Neopla | 1987 |
[UFT therapy of experimental gastric cancer in beagles induced by ENNG].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Dogs; Male; Methylnitronitroso | 1987 |
[Antitumor effect of intermittent oral administration of UFT against human rectal cancer xenografted in nude mice].
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Drug Adm | 1988 |
[Effect of combined BCG and UFT therapy of human maxillary cancer transplanted into nude mice].
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Body Wei | 1988 |
Summation effect of uracil on the two-stage and multistage models of urinary bladder carcinogenesis in F344 rats initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine.
Topics: Animals; Body Weight; Butylated Hydroxyanisole; Butylhydroxybutylnitrosamine; Carcinoma, Transitiona | 1988 |
Production of urinary tract tumors by co-administration of uracil and N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide in F344 rats.
Topics: Animals; Body Weight; Carcinoma; Cocarcinogenesis; FANFT; Female; Hyperplasia; Kidney Pelvis; Rats; | 1987 |
Toxicity study of uracil in dogs.
Topics: Animals; Blood Cell Count; Body Weight; Chromatography, Gas; Dogs; Drinking; Eating; Electrocardiogr | 1985 |
Utilization of nitrogen from selected purines and pyrimidines and from urea by the young chick.
Topics: Adenine; Amino Acids; Animal Nutritional Physiological Phenomena; Animals; Body Water; Body Weight; | 1974 |
Feeding studies on lenacil in the rat and dog.
Topics: Animals; Appetite; Body Weight; Cyclohexanes; Diet; Dogs; Female; Herbicides; Liver; Male; Organ Siz | 1974 |
Orotate as a beta-alanine donor for anserine and carnosine biosynthesis, and effects of actinomycin D and azauracil on their pathway.
Topics: Alanine; Amino Acids; Animals; Autoanalysis; Autoradiography; Body Weight; Carbon Isotopes; Chromato | 1969 |
[Effect of pentoxyl on the effectiveness of antibacterial agents in the treatment of pulmonary tuberculosis].
Topics: Antitubercular Agents; Blood; Body Weight; Heartburn; Humans; Nausea; Respiratory Function Tests; St | 1971 |
Effect of 1-benzyl-2-thio-5,6-dihydrouracil on hepatic metabolic activity in the rat.
Topics: Animals; Body Weight; Carbon Isotopes; Cycloheximide; Depression, Chemical; Hexobarbital; Hydrocorti | 1968 |
[On the anabolic and adaptation inducing action of 4-methyluracil].
Topics: Animals; Blood Proteins; Body Weight; Erythrocyte Count; Hemoglobinometry; Muscle Proteins; Muscles; | 1968 |
Effectof prednisolonon growth and nucleic acid metabolism of Pekin ducks.
Topics: Animal Feed; Animals; Body Weight; Ducks; Growth; Nucleic Acids; Prednisolone; Thymidine; Tritium; U | 1969 |